title: [Detection of erectile dysfunction and peculiarities of its treatment in men with high cardiovascular risk].
abstract: It has been demonstrated in a series of studies that erectile dysfunction (ED) appears to be one of risk factors and predictors of ischemic heart disease (IHD). According to the SSRC PM data in a cohort of 300 men with high cardiovascular risk ED was diagnosed in 61% of cases, while among 300 men with verified diagnosis of IHD was detected in 92.7% of cases. According to recommendations of the European Society of Urology changes of life style and correction of risk factors should precede therapy of ED or be components of complex therapy. It is known that some antihypertensive drugs (nonselective beta-adrenoblockers, thiazide diuretics) can negatively affect erectile function. According to data of comparative randomized clinical study average therapeutic doses of thiazide-like and thiazide diuretics in combination with ACE inhibitors do not worsen erectile function. Data on effect of lipid lowering therapy on erectile function are equivocal. Type 5 phosphodiesterase inhibitors (PDI) are first line preparations for the treatment of patients with ED. Safety of combination of type 5 PDI with main groups of antihypertensive drugs has been demonstrated in persons with risk factors of CVD and ED. The use of type 5 PDI in men depends on degree of compensation of cardiovascular system. In unstable cardiovascular events preparations of this group can be also carefully used. Simultaneous administration of nitrates is a contraindication for type 5 PDI.
authors.forename: M N
authors.initials: MN
authors.lastname: Mamedov
authors.forename: R T
authors.initials: RT
authors.lastname: Digigova
authors.forename: G G
authors.initials: GG
authors.lastname: Sharvadze
authors.forename: Z O
authors.initials: ZO
authors.lastname: Ugurchieva
authors.forename: M N
authors.initials: MN
authors.lastname: Kovrigina
authors.forename: M V
authors.initials: MV
authors.lastname: Stroeva
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D050197:Atherosclerosis / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003863:Depression / Q000209:etiology / Q000503:physiopathology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D008019:Life Style; D008297:Male; D005996:Nitroglycerin / Q000008:administration & dosage / Q000009:adverse effects; D010410:Penile Erection / Q000187:drug effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D058986:Phosphodiesterase 5 Inhibitors; D049993:Sodium Chloride Symporter Inhibitors; D005996:Nitroglycerin